Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Healthy males or females between 18 and 65 years of age (both inclusive) with body mass index between 19 and 30 kg/m2, inclusive, and body weight of not \<50 kg or \>95 kg, will be enrolled in this study.~Exclusion Criteria:~* Hematologic laboratory abnormalities (including leukocytosis \[defined as total leukocytes \>11,000/mcL\], leukopenia \[defined as total leukocytes \<4000/mcL\], or neutropenia \[defined as absolute neutrophil count \<1500/mcL\] or thrombocytopenia \[defined as platelet count of \<150,000/mcL\]) or other clinically significant abnormal laboratory evaluations.~* Lack of adequate hepatic or renal reserve.~* Any active systemic or immunologic disease or condition.~* History of biological growth factor exposure.~* Received live vaccination or exposure to communicable viral diseases within 4 weeks prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PF-06881894 (Type: EXPERIMENTAL): PF-06881894 6 mg SC
- US-approved Neulasta (Type: ACTIVE_COMPARATOR): US-approved Neulasta 6 mg SC

Based on this trial design, predict the completion outcome and termination type (if applicable).